Cathie Wood’s ARK buys CRISPR, sells Adaptive Biotech stock

Cathie Wood’s ARK ETFs have made their daily trades for Thursday, 29 May 2025, with a notable increase in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) and a continued sell-off of Adaptive Biotechnologies Corp (NASDAQ:ADPT).

ARK’s largest transaction for the day was the purchase of 294,249 shares of CRISPR Therapeutics AG, split between its ARKK and ARKG ETFs, amounting to a total dollar value of approximately $10.95 million. This move indicates ARK’s growing confidence in the gene-editing company, which has been a recurring target for the fund’s investments, suggesting a bullish outlook on the firm’s prospects.

Simultaneously, ARK has been reducing its position in Adaptive Biotechnologies, selling 163,700 shares through its ARKG ETF, resulting in a sale value of around $1.5 million. This follows a pattern of sales from the previous days, highlighting a potential strategic shift away from the company by ARK.

Other significant trades include the sale of shares in 3D Systems Corp (NYSE:DDD) across two ETFs—ARKQ and ARKX—for a total value of approximately $379,500, and the sale of Roblox Corp (NYSE:RBLX) stock worth about $861,296 through its ARKW ETF. These sales could signal ARK’s reevaluation of the companies’ future growth potential or a simple rebalancing of the funds’ portfolios.

On the buying side, ARK has continued to invest in Illumina Inc (NASDAQ:ILMN), acquiring an additional 3,233 shares through ARKG, valued at $269,018. This follows a trend of consistent buying in the biotech company, suggesting ARK’s positive stance on the genomics sector.

Investments were also made in Iridium Communications Inc (NASDAQ:IRDM), L3Harris Technologies Inc (NYSE:LHX), and Intellia Therapeutics Inc (NASDAQ:NTLA), with ARK buying 3,850, 1,214, and 201,476 shares respectively. The total dollar values for these purchases were $98,868 for IRDM, $296,665 for LHX, and approximately $1.95 million for NTLA, highlighting ARK’s interest in the communications and defense sectors, as well as its continued focus on innovative biotech firms.

Smaller transactions included the sale of UiPath Inc (NYSE:PATH) and Ionis Pharmaceuticals Inc (NASDAQ:IONS) stocks, which might reflect minor portfolio adjustments based on the funds’ strategic objectives.

ARK’s daily trading activities suggest a strategic focus on specific sectors, such as biotechnology and genomics, while also indicating shifts in confidence regarding individual companies. Investors following ARK’s trades can glean insights into the fund’s market outlook and portfolio management strategies, which are characterized by a strong emphasis on disruptive innovation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.